touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • Adverse event identification and management in locally advanced/metastatic urothelial carcinoma

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen to an oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies for locally advanced or metastatic urothelial carcinoma. 

    The experts:

    • Dr Axel Merseburger, University Hospital Schleswig-Holstein, Campus Lübeck, Germany
  • Dr André Fay, PUCRS School of Medicine, Porto Alegre, Brazil
  • Ms Maria Lapuente, St Bartholomew’s Hospital, London, UK

    • This touchPODCAST is for HCPs outside the US only. 

    This activity is funded by an independent medical education grant from Astellas Inc. and Seagen Inc., and is jointly provided by USF Health and touchIME.

    For further information please visit: https://touchoncologyime.org/adverse-event-identification-and-management-in-locally-advanced-metastatic-urothelial-carcinoma

    40 min
  • Experts in infectious diseases discuss the practical considerations for COVID-19 vaccination in the Middle East

    touchIN CONVERSATION for touchINFECTIOUS DISEASES

    Listen to Dr Farhan Fazal (Sheikh Khalifa Medical City Hospital, Abu Dhabi, UAE) in conversation with Dr Nada Melhem (American University of Beirut, Beirut, Lebanon). They respond to questions submitted by the HCP audience and provide their expert insights on COVID-19 vaccination challenges and strategies for improving vaccine uptake in the Middle East.

    This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from Moderna, Inc. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchinfectiousdiseasesime.org/in-conversation-practical-considerations-covid19-vaccination-middle-east/

    38 min
  • Module 1 Addressing the burden of migraine - The role of anti-CGRP antibodies in practice
    touchCLINICAL PERSPECTIVES for touchNEUROLOGY
    Addressing the burden of migraine - The role of anti-CGRP antibodies in practice
    Listen to an expert provide their insights on the burden of migraine for patients, the need for effective preventive therapy and the currently available preventive treatment options.
    The expert:
    Prof. Simona Sacco, University of L’Aquila, Italy
    This touchPODCAST is for HCPs only.
    This activity is funded by an educational grant from Eli Lilly and Company Limited. This medical education is provided by touchIME.
    For further information visit our website: https://touchneurology.com/the-role-of-anti-CGRP-antibodies-in-migraine-prevention/
    13 min
  • Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals

    touchEXPERT OPINIONS for touchENDOCRINOLOGY

    In this first of a two-part series, a medical physicist and a radiation oncologist provide a scientific and clinical primer on radiopharmaceuticals in adult oncology.

    The experts:

    • Dr Stephen Graves, University of Iowa, Iowa City, IA, USA
  • Dr Ana Kiess, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

    • This touchPODCAST is for HCPs only.

     This activity is funded by an independent medical education grant from Advanced Accelerator Applications International S.A and is jointly provided by USF Health and touchIME.

    For further information visit: https://touchendocrinologyime.org/radiopharmaceuticals-adult-oncology-primer/


    21 min
  • Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals

    touchEXPERT OPINIONS for touchONCOLOGY

    In this first of a two-part series, a medical physicist and a radiation oncologist provide a scientific and clinical primer on radiopharmaceuticals in adult oncology.

    The experts:

    • Dr Stephen Graves, University of Iowa, Iowa City, IA, USA
  • Dr Ana Kiess, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Advanced Accelerator Applications International S.A. This activity is jointly provided by USF Health and touchIME.

    For further information visit: https://touchoncologyime.org/radiopharmaceuticals-adult-oncology-primer/ 


    21 min
  • Experts in infectious diseases discuss the practical considerations for COVID-19 vaccination in Africa

    touchIN CONVERSATION for touchINFECTIOUS DISEASES

    Listen to Dr John Amuasi (Kwame Nkrumah University of Science and Technology, Kumasi, Ghana) in conversation with Dr Christina Obiero (Kenya Medical Research Institute, Kilifi, Kenya). They respond to questions submitted by the HCP audience and provide their expert insights on COVID-19 vaccination challenges and strategies for improving vaccine uptake in Africa.

    This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from Moderna, Inc. This activity was led by USF Health and touchIME. 

    For further information visit our website: https://touchinfectiousdiseasesime.org/in-conversation-practical-considerations-covid19-vaccination-africa

    41 min
  • Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

    touchEXPERT OPINIONS for touchONCOLOGY

    Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).

     The experts:

    • Prof. Andrew Wei, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
  • Prof. Agnieszka Wierzbowska, Medical University of Lodz, Poland
  • Prof. Gert Ossenkoppele, Vrije Universiteit University Medical Center, Amsterdam, Netherlands

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Novartis and is provided by touchIME. 

    For further information visit: www.touchoncology.com/education/impact-of-new-guidelines-in-MDS-AML 

    36 min
  • Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

    touchEXPERT OPINIONS for touchHAEMATOLOGY

    Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).

     The experts:

    • Prof. Andrew Wei, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
  • Prof. Agnieszka Wierzbowska, Medical University of Lodz, Poland
  • Prof. Gert Ossenkoppele, Vrije Universiteit University Medical Center, Amsterdam, Netherlands

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Novartis and is provided by touchIME. 


    For further information visit: www.touchhaematology.com/education/impact-of-new-guidelines-in-MDS-AML 

    36 min
  • Clinical updates from SGO 2023 on PARP inhibitors in ovarian cancer

    touchCONGRESS for touchONCOLOGY

    Listen to renowned experts in gynaecological oncology Dr Domenica Lorusso, Dr Susana Banerjee and Prof. Frederik Marmé review key data presented at SGO 2023 on recent developments in the use of PARP inhibitors in ovarian cancer. Aspects covered include first-line maintenance therapy, selection and sequencing implications, and future directions including emerging neoadjuvant and combination regimens. They also discuss how these latest data may impact clinical practice.

    Clinical themes:

    1. Update on first-line PARP inhibitor maintenance in ovarian cancer: Where are we now? (02:31)
  • Selection and sequencing implications for PARP inhibitors in ovarian cancer emerging from the latest data: What should we consider, and when? (19:51)
  • Emerging PARP inhibitor-based neoadjuvant and combination regimens in ovarian cancer: Where are we heading? (40:10)

    • The internationally renowned expert faculty: 

    • Dr Domenica Lorusso, Fondazione Policlinico Universitario A Gemelli, Rome, Italy
  • Dr Susana Banerjee, The Royal Marsden NHS Foundation Trust, London, UK
  • Prof. Frederik Marmé, University Hospital Heidelberg, Heidelberg, Germany

    • This touchPODCAST is for HCPs outside of the USA only.

    This activity is funded by an independent medical education grant from GlaxoSmithKline, and is provided by touchIME.

    For further information visit our website: https://touchoncology.com/education/congress-sgo-2023-updates-parp-inhibitors-ovarian-cancer/

     

    1 hr 2 min
  • Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach

    touchEXPERT OPINIONS for touchRESPIRATORY

    Listen to three experts as they share their perspectives and best-practice guidance on how to optimize the diagnosis and management of pulmonary arterial hypertension.

    The experts:

    • Prof. Harrison Farber, Tufts Medical Center, Boston, MA, USA
  • Prof. Marion Delcroix, University Hospitals Leuven, Belgium
  • Prof. Stephan Rosenkranz, University of Cologne, Germany

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Merck & Co. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website: https://touchrespiratoryime.org/improving-outcomes-in-pulmonary-arterial-hypertension-a-multidisciplinary-approach/

    36 min

About touchPODCAST

From the publisher's feed

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.